IPHU A2M conclusion
1-Have you attended any training on Intellectual Property & Access to Medicines?
2-If yes to above question. Do provide us the Year, Name of Training, Organizer ( upto 3 ).
3- Many countries do not allocate sufficient funds for health in general, and medicines specifically. Therefore it is far-fetched to blame patent protection for lack of access to medicines.” Do you agree? Provide at least one reason to support your answer.
4-“Patent protection is an incentive for the R&D investment in pharmaceuticals”. Is there any exception to this statement?
5- Country X issued a “government use” license for treatment for lifestyle diseases (e.g. related to smoking, alcohol consumption) . Is it justifiable under the WTO-TRIPS Agreement? Provide at least one reason for your answer.
6-“Countries are legally permitted to provide patent protection for a period that is more than 20 years, according to the WTO-TRIPS Agreement”. Do you agree with this provision? Provide at least one reason to support your answer.
7-Which of the following countries are required by the WTO-TRIPS Agreement to provide pharmaceutical patent protection?
Ghana ( Developing Country)
Iran (non-WTO member)
8-Which of the following patent claims are deserving of patent protection?
combination of existing compound X and compound Y
heat stable formulation of known compound Z
compound B, a newly found chemical entity
compound W (previously used for treatment of HIV/AIDS), now developed for the treatment of cancer)
9- The WTO-TRIPS Agreement does not allow the use of originator companies’ clinical trial data to approve the generic version. Is it true? Cite at least one reason for your answer.
10- Explain what are “TRIPS-plus” provisions. Give 2 examples of such provisions and describe the provisions and the impact on access to affordable medicines.
11- The European Union and Country X are negotiating a free trade agreement and TRIPS-plus measures are being discussed. Which of the following options would you advise Country X to accept, if Country X had to agree to TRIPS-plus provisions?
Each Party shall make best efforts to process patent applications in an efficient and timely manner, with a view to avoiding unreasonable or unnecessary delays.
Each Party shall make available an adjustment of the patent term to compensate the patent owner for unreasonable curtailment of the effective patent term as a result of the marketing approval process.
12-Counterfeit medicines always kill patients”. Do you agree? Provide at least one reason to support your answer.
Never submit passwords through Google Forms.
This form was created inside of People's Health Movement.
Terms of Service